R
Richard N. Clayton
Researcher at Keele University
Publications - 118
Citations - 8946
Richard N. Clayton is an academic researcher from Keele University. The author has contributed to research in topics: Loss of heterozygosity & Adenoma. The author has an hindex of 52, co-authored 116 publications receiving 8544 citations. Previous affiliations of Richard N. Clayton include Diabetes Australia & University Hospitals of North Midlands NHS Trust.
Papers
More filters
Journal ArticleDOI
The EFEMP1 gene: a frequent target for epigenetic silencing in multiple human pituitary adenoma subtypes
TL;DR: The protein product of the EF EMP1 gene, fibulin-3, is reported to impact on multiple pathways in a cell-specific context and subtype-independent loss of EFEMP1 expression in the majority of primary adenomas should prompt more detailed investigation in this tumour type.
Journal ArticleDOI
Pituitary tumours are multiclonal from the outset: evidence from a case with dural metastases
H. N. Buch,Tarik Elhadd,John E. Bicknell,David J. Simpson,William E. Farrell,Richard N. Clayton +5 more
TL;DR: Genetic analysis of the initial pituitary tumour identified significant allelic losses in keeping with its invasive nature, while that of the metastases indicated a separate clone as shown by retention of alleles lost in the primary tumour.
Journal ArticleDOI
Do polycystic ovaries on ultrasound scan indicate decreased insulin sensitivity in sisters of women with polycystic ovary syndrome
TL;DR: Data suggest that presence of PCO on ultrasound scan per se does not predispose to reduced insulin sensitivity in sisters of women with PCOS, and it is important that future studies take full account of the contribution made by obesity to risk factors for metabolic/vascular complications.
Journal ArticleDOI
Tumour suppressor genes in pituitary tumour formation
TL;DR: Methylation may provide a unifying mechanism preceding and predisposing towards allelic loss, and in other cases leading to reduced tumour suppressor gene expression, and the re-expression of genes silenced through this mechanism offer considerable therapeutic potential.
Journal ArticleDOI
Molecular biology of human pituitary adenomas.
TL;DR: A tentative map is drawn showing loss of heterozygosity at several chromosomal loci to be associated with the transition to the invasive and malignant phenotype, while changes associated with chromosome 9p and silencing, through methylation, of the tumour suppressor gene p16 appear to occur early in pituitary tumourigenesis.